| Issue Date | Title | Author(s) |
| 27-Apr-2024 | Effect of MYC and PARP Inhibitors in Ovarian Cancer Using an In Vitro Model | Morea, A; Saravi, S; Sisu, C; Hall, M; Tosi, S; Karteris, E; Storlazzi, CT |
| 2-Sep-2020 | H2A Histone Family Member X (H2AX) Is Upregulated in Ovarian Cancer and Demonstrates Utility as a Prognostic Biomarker in Terms of Overall Survival | Saravi, S; Katsuta, E; Jeyaneethi, J; Amin, HA; Kaspar, M; Takabe, K; Pados, G; Drenos, F; Hall, M |
| 20-Dec-2021 | Host cell entry mediators implicated in the cellular tropism of SARS‑CoV‑2, the pathophysiology of COVID‑19 and the identification of microRNAs that can modulate the expression of these mediators (Review) | Katopodis, P; Randeva, HS; Spandidos, DA; Saravi, S; Kyrou, I; Karteris, E |
| 4-Aug-2023 | Identification of RAD51 foci in cancer-associated circulating cells of patients with high-grade serous ovarian cancer: Association with treatment outcomes | Alizzi, Z; Saravi, S; Khalique, S; Mcdonald, T; Karteris, E; Hall, M |
| 30-Jan-2024 | In Silico and In Vitro Mapping of Receptor-Type Protein Tyrosine Phosphatase Receptor Type D in Health and Disease: Implications for Asprosin Signalling in Endometrial Cancer and Neuroblastoma | Orton, S; Karkia, R; Mustafov, D; Gharanei, S; Braoudaki, M; Filipe, A; Panfilov, S; Saravi, S; Khan, N; Kyrou, I; Karteris, E; Chatterjee, J; Randeva, HS |
| 15-Sep-2021 | Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of Brca2 Status | Saravi, S; Alizzi, Z; Tosi, S; Hall, M; Karteris, E |
